Jade Corporate Presentation
Jade Biosciences is focused on developing innovative, best-in-class therapies to address critical unmet needs in autoimmune diseases.
Our lead candidate, JADE101, is designed to inhibit the cytokine APRIL (A Proliferation-Inducing Ligand) and is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a chronic kidney disease that can impair kidney function over time. JADE101 aims to reduce harmful IgA antibodies, lower proteinuria (a key marker of kidney damage), and preserve long-term kidney function. A Phase 1 healthy-volunteer study of JADE101 is ongoing, with interim, biomarker-rich data expected in the first half of 2026.
Jade’s pipeline also includes a second development candidate, JADE201, an anti-BAFF-R (B-cell activating factor receptor), and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development. See our pipeline to learn more.
Events
No upcoming events are scheduled. View past events or subscribe to Investor alerts to stay informed.
Past events Past events Investor alerts Visit the Investor Alerts page